

Supplementary information

Long-term Safety and Efficacy of CART-20 Cells in Patients with Refractory or Relapsed B-Cell Non-Hodgkin Lymphoma: 5-years follow-up results of the phase I and IIa trials

Wen-ying Zhang^{1*}, Yang Liu^{2*}, Yao Wang^{3*}, Chun-meng Wang¹, Qing-ming Yang¹,
Wei-dong Han^{1,3#}, Hong-li Zhu^{2#}


1 Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, China

2 Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing 100853, China

3 Department of Immunology, Institute of Basic Medicine, School of Life Sciences, Chinese PLA General Hospital, Beijing 100853, China

*Contributed equally to this work

Supplement Figure



Supplement Figure. The CD19⁺ lymphocyte cells also were determined by flow cytometry in PB after CART-20 cell infusion is shown. From 1 week after infusion, the proportion began to decline, and it lasted for over 150 weeks.